ProMIS Neurosciences : Corporate Overview

Corporate Presentation

Legal Disclaimers

This slide deck may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on ProMIS Neurosciences Inc.'s (the "Company") current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this slide deck. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings available online at sec.gov, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Pioneering Solutions for Neurodegenerative Diseases

ProMIS uses Precision Medicine and Artificial Intelligence to develop novel drugs to treat dementia and neurodegenerative diseases

Dementia Disorders

•  Alzheimer's Disease

•  Amyotrophic Lateral Sclerosis (ALS)

•  Parkinson's Disease

•  Multiple System Atrophy

•  Lewy Body Dementia

The Challenge: Impaired Cognition

•  According to the World Health Organization, currently more than 55 million people have dementia worldwide

•  There are nearly 10 million new cases diagnosed every year1

•  Dementia is a term for several diseases that affect memory, thinking, and the ability to perform daily activities

•  Dementia can lead to death, as it affects the brain and other vital organs

•  Dementia is currently the seventh leading cause of death and one of the major causes of disability and dependency among older people, globally

•  In the US, Alzheimer's disease, the most common form of dementia, the Alzheimer's Association reported that over 82,000 people died from Alzheimer's disease in 2019

1WHO Fact sheet

Misfolded Proteins: A Leading Cause of Dementia and Neurodegeneration

• • Proteins play crucial roles in various cellular functions, and their proper folding is essential for maintaining cellular health.

• • However, misfolding, the process in which a protein fails to adopt its correct three-dimensional structure, is a common occurrence.

• • Misfolded proteins can arise due to genetic mutations, environmental factors, or errors in cellular processes.

• • The gradual and inevitable nature of protein misfolding is part of the aging process

• • When proteins misfold, they often lose their functional integrity and may acquire toxic properties.

• • Misfolded proteins can aggregate, forming pathogenic clumps that interfere with normal cellular processes.

• • These protein aggregates are a hallmark of several neurodegenerative diseases

(folded structure)Disease associated protein

(misfolded)

Toxic

Image adapted from Racaniello V et al, virology.ws, 2016

Loss of biological function

The ProMIS Solution

ProMIS has created a Novel, Unique, Patent Protected, Targeted platform to:

• 1. Predict disease-specific misfolding of proteins and identify unique binding sites (epitopes) on each of these misfolded proteins.

• 2. Create novel antibodies that bind strongly only to the specific epitopes allowing the body's immune system to selectively target and eliminate these toxic proteins from the brain

3. Objective: Slow or Halt Disease Progression

Misfolded proteins are different for each disease. Therefore, the platform can provide highly specific drug candidates for multiple diseases

Ab binds epitope on misfolded protein

1 The company plans to investigate additional synucleinopathies, including Parkinson's disease and dementia with Lewy bodies 2Initial indication AD: Alzheimer's disease, ALS: Amyotrophic lateral sclerosis, MSA: Multiple system atrophy, HD: Huntington's disease, FTLD: Frontotemporal lobar degeneration, PSP: Progressive supranuclear palsy, CBD: Corticobasal degeneration

ProMIS Computational Platform and Rational Design Capabilities Enabled the Creation of PMN310

Identification of regions (conformational epitopes) likely to be exposed in misfolded toxic Aβ oligomers but not in monomers or fibrils

6-8 months to drug candidates

Copyright 2024, ProMIS Neurosciences, Inc.

Gibbs et al, 2019, Scientific Reports

ProMIS Extensive Patent Estate

• • Over 125 total patent filings for entire portfolio, growing

• • Global patent estate: Applications have been filed in the US, CA, with the EPO, Japan, and other globally strategic regions

• • Extensive patent estate for the amyloid area (PMN310 plus other antibodies)

  • • 9 issued patents and 43 pending

  • • Patent coverage for PMN310 in US until 2036, plus potential data exclusivity extensions to 2042

  • • Three-pronged IP strategy

    • 1. Composition of Matter: Methods & Systems for Predicting Misfolded Peptide Epitopes (two computational algorithms, ProMISTM and Collective Coordinates)

    • 2. Immunogens and methods directed to these disease-specific epitopes

    3. Methods of use: antibodies targeting disease specific epitopes, and methods of use thereof

Experienced Leadership Team

Executive Management

Gavin Malenfant Chief Operating Officer

David Wishart, Ph.D.

Chief Physics Officer

Board of Directors

Dan Geffken Chief Financial Officer

10

Attachments

• Original Link
• Original Document
• Permalink

Disclaimer

ProMIS Neurosciences Inc. published this content on 29 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 March 2024 11:40:04 UTC.